written by reader Jeff Browns “Penny IPO`s”

By Zeflik, May 21, 2020

Does anyone could guess which `biotech/medical stock Jeff Brown is promoting in the ”Penny IPO`s” pitch? All of them have potential for at least 10x growth. Here is the link to the pitch https://secure.bonnerandpartners.com/?cid=MKT459805&eid=MKT463356&step=start&plcid=PLC069177&SNAID=SAC0010464081&email=jozef.szlufcik@gmail.com&encryptedSnaid=mtFugfkIjQZwvQduYvOPoJkMUqW8Rkx1t2V4kZtac6o%3D&emailjobid=4646829&emailname=20200520-TBE-F&assetId=AST136084&page=2
Grtx,
Zeflik

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

12 Comments
Inline Feedbacks
View all comments
👍 76
dssgateway1
Irregular
dssgateway1
May 21, 2020 1:15 pm
Reply to  Zeflik

WHAT ARE THEY?

👍 3
dssgateway1
Irregular
dssgateway1
May 21, 2020 1:12 pm

ANY IDEAS HERE

👍 3
mclovin
Member
mclovin
May 27, 2020 4:12 am

I have not subscribed to the ipo service but have seen the presentation. I’m also in healthcare and familiar with the fda process. I believe IPO 3 is Editas for a few reasons.

In this presentation, and a few others he’s done for other services, there are slides that appear showing FDA trial data. Trial number can be seen, and in a different video for another service, the actual company was shown. Im sure that was a mistake. But the trial numbers were the same across both.

Crisper (gene editing) is patented and only used by a handful of companies. In this presentation, in the background, one can see LCA-10 in a slide that is a bit blurry. This is Leber Congenital Amarousis (congenital blindness). By searching publicly-available trial data, the only company that comes up as having a phase 1/2, in vivo, ongoing trial for autosomal dominant LCA is Editas.

This is it: https://clinicaltrials.gov/ct2/show/NCT03872479

In other slides, current share price is shown and also fits at 20-30, currently around $27 I believe, as does it’s current market cap.

In-vivo gene editing, if successful, would be a first-in-class therapy. Editas also has a few other potential gene targets for other conditions.

I haven’t researched ipo 1 or 2 yet. Interested to hear others’ thoughts.

👍 2
👍 76
mclovin
Member
mclovin
May 30, 2020 1:59 am
Reply to  Zeflik

Agree. Early stage for sure but a penny stock it is not. But if their phase II comes through, and they are the first to cure a major genetic condition with gene editing, the sky’s the limit.

I looked into IPO #1 and think it’s kaleido (kldo). Jeff Gordon is collaborating, they have a focus on using the microbiome to treat hepatic encephalopathy (sequela of cirrhosis), partnership with Janesson, a division of J&J tasked with treating pediatric atopic (allergic) conditions, and they are a microcap in target price range with a planned phase II trial this summer.

Pencil
Member
Pencil
June 26, 2020 4:19 am

This is my opinion only, based on the (misleadingly annotated) charts in Jeff’s presentation and cross-referencing some of the info he shares with Crunchbase: 1 – KLDO, 2 – DTIL, 3 – EDIT.

👍 4
BA7
Guest
BA7
June 29, 2020 6:52 am
Reply to  Pencil
brandi
Member
brandi
July 14, 2020 4:32 pm
Reply to  BA7

i am considering subscribing, are you and actual subscriber and are you please with the service?

docdavidw
Irregular
July 14, 2020 5:30 pm
Reply to  brandi

I am a paying irregular for several years, so yes, I am happy with it

brandi
Member
brandi
July 17, 2020 7:12 am
Reply to  docdavidw

THANKS! i have dug a little more and i am ready to take the plunge… happy trading!

Dennis Richardson
Guest
Dennis Richardson
October 6, 2020 7:32 pm

How do I but stock? Where in north California do I but it. How do i buy it on the Internet?